tryptase


Also found in: Wikipedia.

tryptase

(trip'tās),
A neutral protease released from mast cells during cellular activation and degranulation.
[trypt-, fr. trypsin, fr. G. tripsis, a rubbing or grinding, + -ase]

tryptase

tryp·tase

(trip'tās)
A neutral protease released from mast cells during cellular activation and degranulation.
[trypt-, fr. trypsin, fr. G. tripsis, a rubbing or grinding, + -ase]

tryptase (trip´tās),

n See plasmin.

tryptase

a protease that is active in inflammation and a mediator of anaphylaxis.
References in periodicals archive ?
However, the mast cell tryptase is also elevated in systemic mastocytosis, and although this condition may be manifest by skin pigmentation, unexplained diarrhoea or abdominal pain, or musculoskeletal pain or episodes of hypotension, it may be previously unsuspected, as in this case.
Celera has solved the crystal structures of both Factor VIIa and tryptase in the presence of small molecule inhibitors.
The Schwann cell markers, S100 protein, and 2'2'-cyclic nucleotide 3' phosphodiesterase (CNPase), the neuronal markers synaptophysin, neuron-specific enolase (NSE), and mast cell tryptase expression, was determined by incubation overnight at 4 [degrees] C with commercially available primary antibody, followed by incubation with appropriate biotinylated secondary antibody (Dako, Glostrup, Denmark) and strepABCcomplex or ABCcomplex (Dako), prepared according to the manufacturer's instructions.
While various preclinical small molecule programs have continued to move forward, toxicology and safety evaluations of the lead tryptase inhibitor for asthma originally planned for the recent quarter were not undertaken.
Celera Genomics intends to advance its most promising small molecule compounds, such as tryptase inhibitors for asthma and allergic rhinitis and its Factor VIIa inhibitors for anticoagulation, forward into clinical development.
Celera Genomics intends to advance its most advanced small molecules programs, such as its Factor VIIa inhibitors for anticoagulation and tryptase inhibitors for asthma and allergic rhinitis, into clinical trials on its own account.
In October 2002, Celera Genomics purchased a number of pre-clinical oral tryptase inhibitors for the treatment of asthma from Bayer AG.
Axys said it does not expect to incur further development expense for the compound and is concentrating on the oral tryptase program with Bayer.
Like the Delta technology, which remains the basis for oral inhibitors of tryptase under preclinical study by Bayer AG, the new scaffold design paradigm yields inhibitors that are non-peptide, not dependent on chiral centers for activity, and have low molecular weights.
Nasdaq:AXPH) today announced a newly amended agreement with Bayer AG of Leverkusen, Germany that provides Axys exclusive rights to develop a specific tryptase inhibitor, APC 2059, as a potential inhaled therapy for asthma and as an injectable treatment for ulcerative colitis.
APC 2059 is a small molecule tryptase inhibitor that was delivered in this study by subcutaneous injection.